6949 — Pell Bio Med Technology Co Income Statement
0.000.00%
Last trade - 00:00- TWD8.17bn
- TWD7.61bn
- TWD19.63m
Annual income statement for Pell Bio Med Technology Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 14 | 17.2 | 18 | 19.6 |
| Cost of Revenue | ||||
| Gross Profit | -4.37 | -11.3 | -26.1 | -12.3 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 207 | 253 | 429 | 433 |
| Operating Profit | -193 | -236 | -411 | -413 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -189 | -231 | -401 | -395 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -189 | -231 | -401 | -395 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -189 | -230 | -399 | -389 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -189 | -230 | -399 | -389 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -4.16 | -4.98 | -8.62 | -6.82 |
| Dividends per Share |